Nanobac Pharmaceuticals Inc. Announces Agreement to Validate Proof That Nanobacteria Promote Gallstones
Wednesday August 23, 9:35 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Aug. 23, 2006--Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP - News; "Nanobac" or "the Company") today announced that it has entered into an agreement and started work on an animal model to validate a proof of concept that calcifying nanoparticles (CNPs), also known as nanobacteria, promote gallstones.
If the proof is validated, it will solve the ages-old mystery of what provokes black pigment gallstones affecting millions of persons, and forge a path to effective early diagnosis and therapy where none are presently available. Results are expected by year-end 2006. Because these gallstones contain material similar to that in kidney stones and breast cancer calcifications, the results could apply to other unsolved calcification-related conditions as well.
The agreement was signed with the same scientific team who, in "An Animal Model of Black Pigment Gallstones Caused by Nanobacteria" published in the June 2006 edition of the peer-reviewed journal Digestive Diseases and Sciences, established that calcifying nanoparticles promote black pigment gallstones in rabbits when injected into the gallbladder.
The study concludes, "We successfully cultured nano-sized particles coated with hydroxyapatite from human gallbladder bile and confirmed that they were nanobacteria by their typical growth rates, optical properties, specific stainability with Hoechst 33258, and by immunologic methods. By the animal experiment, we demonstrated for the first time that black pigment gallstones could be promoted by nanobacterial infection."
The initial study was conducted independent of Nanobac Pharmaceuticals and was not funded from any corporate source. Abstract of that study is available at PubMed by entering the study title at this website: ncbi.nlm.nih.gov
The Principle Investigator is Dr. LiMin Wang, from Shantou University Medical College, Guangdong, China. Results will be verified by a team consisting of a former Merck executive and other U.S. experts in urology and infectious diseases.
Nanobac is the only Company with regulatory approval of diagnostics that can accurately identify these calcifying particles. The Company is also expecting to start a clinical trial on a promising therapy for such stone-forming diseases by the fourth quarter of 2006.
About Nanobac Pharmaceuticals
Nanobac Pharmaceuticals, Inc. is a life sciences company dedicated to the discovery and development of products and services to improve people's health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as "nanobacteria". The Company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate, and vascular disease.
Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting Calcifying Nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.
Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: nanobac.com .
Contact:
Nanobac Pharmaceuticals, Inc., Tampa
Douglas Mulhall, 813-264-2241
dmulhall@nanobaclabs.com
or
Redwood Consultants, LLC
415-884-0348
InvestorInfo@RedwoodConsultants.com
Source: Nanobac Pharmaceuticals, Inc. |
